id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_6i2iwigggrfblefghe5hbmdfsu	Roger L. Novack	Safety of Intravitreal Ocriplasmin for Focal Vitreomacular Adhesion in Patients with Exudative Age-Related Macular Degeneration	2015	3	.pdf	application/pdf	1963	156	57	patients with neovascular AMD treated with anti-VEGF Mean age in the non-VMA group A 79-year-old man with neovascular AMD in the left eye was treated with one intravitreal bevacizumab injection A 79-year-old man with neovascular AMD in the left eye was treated with one intravitreal bevacizumab injection the non-VMA group (63% at year 2 compared with 54%, Patients in the non-VMA group The clinic utility of treating VMA associated with neovascular AMD was recently explored by Novack and coworkers12 as they investigated the use of intravitreal ocriplasmin 100 patients with VMA and wet AMD to compare combination therapy (ocriplasmin plus anti-VEGF) versus sham treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Influence of vitreomacular interface on anti-VEGF therapy using treat and extend treatment 	./cache/work_6i2iwigggrfblefghe5hbmdfsu.pdf	./txt/work_6i2iwigggrfblefghe5hbmdfsu.txt